Clinical TrialsWith supportive safety data announced from the topline 52-week ENLIGHTEN-1 safety extension study, it was helpful to see LYR-210 safety was generally well tolerated and consistent with the 24-week treatment and including repeat dosing in the 12-month treatment period.

Financial PerformanceLYRA reported EPS of $(0.18) versus consensus of $(0.22), showing better than expected financial performance.

Regulatory PathwayLYRA aims to meet with the FDA to discuss a potential registrational path for LYR-210, which could provide valuable feedback.

Bears Say

Clinical TrialsFollowing the prior Phase 3 ENLIGHTEN-1 failure for mometasone furoate corticosteroid nasal implant LYR-210 in surgically naïve chronic rhinosinusitis (CRS) patients, there is uncertainty about the success of the ongoing Phase 3 ENLIGHTEN-2 trial.

Financial PerformanceThe company reported a net loss of $11.9M, or $0.18/share, indicating financial challenges.

Regulatory UncertaintyThere is a current lack of clarity around an approval path for LYR-210 and uncertainty around the outcome of the ENLIGHTEN II trial.

---

Financials

Annual

Income Statement >

Ownership Overview

9.11% Insiders

3.95% Mutual Funds

25.91% Other Institutional Investors

53.83% Public Companies and Individual Investors

Detailed Ownership Overview >

Risk Analysis

Main Risk Category

Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Detailed Risk Analysis >

LYRA FAQ

What was Lyra Therapeutics, Inc.’s price range in the past 12 months?

Lyra Therapeutics, Inc. lowest stock price was $0.16 and its highest was $6.79 in the past 12 months.

What is Lyra Therapeutics, Inc.’s market cap?

Lyra Therapeutics, Inc.’s market cap is $12.25M.

When is Lyra Therapeutics, Inc.’s upcoming earnings report date?

Lyra Therapeutics, Inc.’s upcoming earnings report date is Mar 05, 2025 which is in 46 days.

How were Lyra Therapeutics, Inc.’s earnings last quarter?

Lyra Therapeutics, Inc. released its earnings results on Nov 12, 2024. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.215 by $0.035.

Is Lyra Therapeutics, Inc. overvalued?

According to Wall Street analysts Lyra Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Lyra Therapeutics, Inc. pay dividends?

Lyra Therapeutics, Inc. does not currently pay dividends.

What is Lyra Therapeutics, Inc.’s EPS estimate?

Lyra Therapeutics, Inc.’s EPS estimate is -0.12.

How many shares outstanding does Lyra Therapeutics, Inc. have?

Lyra Therapeutics, Inc. has 65,457,650 shares outstanding.

What happened to Lyra Therapeutics, Inc.’s price movement after its last earnings report?

Lyra Therapeutics, Inc. reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.215. Following the earnings report the stock price went down -28.571%.

Which hedge fund is a major shareholder of Lyra Therapeutics, Inc.?

Currently, no hedge funds are holding shares in LYRA

---

Company Description

Lyra Therapeutics, Inc.

Lyra Therapeutics Inc a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company's technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration.

---